RT期刊文章SR电子T1对COPD JF慢性支气管炎患者的计量冷冻喷雾的前瞻性安全性和可行性研究188bet官网地址L. A1 Shaipanich，Tawimas A1 Hartman，Jorine E. A1 Orton，Christopher M. A1 Caneja，Cielito A1 Klooster，Karin A1 Thornton，John A1 Sin，Don D. A1 Slebos，D. A1 Slebos，Dirk-Jan A1 Shah，Pallav L. Yr 2020ul //www.qdcxjkg.com/content/56/6/6/2000556.ABSTRACT AB背景没有当前批准的干预措施来抵消COPD中慢性支气管炎的Airway Metaplasia和粘液过度分泌。然而，计量的冷冻喷雾（MCS）将液氮输送到气管机管气道植物异常上皮，并促进健康的粘膜再生。这项研究的目的是评估MC在慢性支气管炎中的可行性，功效和安全性。募集了招募最佳药物的30-80％的30-80％的强迫呼气量的患者。主要结果是可行性（治疗的完成），功效（St George的呼吸问卷发生了3个月的变化（SGRQ））和安全性（不良事件的发生率）。次要结局是肺功能，运动能力和其他患者报告的结果。病例35例，19名男性/16岁的女性，年龄47-76岁，全球慢性阻塞性肺疾病I级I级（n = 3），II（n = n =）10）和iii（n = 22），对气管支出树进行了交错的液氮处理。34例患者完成了三项治疗，每例持续34.3±12.1分钟，分别为4-6周。第一次治疗后撤回了。输送了约1800剂MC。 Clinically meaningful improvements in patient-reported outcomes were observed at 3 months: change in SGRQ −6.4 (95% CI −11.4 to −1.3; p=0.01), COPD Assessment Test (CAT) −3.8 (95% CI −6.4 to −1.3; p<0.01) and Leicester Cough Questionnaire (LCQ) 21.6 (95% CI 7.3 to 35.9; p<0.01). Changes in CAT were durable to 6 months (−3.4, 95% CI −5.9 to −0.9; p=0.01); changes in SGRQ and LCQ were durable to 9 months (−6.9, 95% CI −13.0 to −0.9; p=0.03 and 13.4, 95% CI 2.1 to 24.6; p=0.02, respectively. At 12 months, 14 serious adverse events were recorded in 11 (31.4%) subjects; six (43%) moderate and eight (57%) severe. Nine were respiratory-related: six exacerbations of COPD, two pneumonias and one case of increased coughing; all recovered without sequelae. None were serious device- or procedure-related adverse events.Conclusion MCS is safe, feasible and associated with clinically meaningful improvements in multidimensional patient-reported outcomes.RejuvenAir system treatment for individuals with chronic bronchitis in COPD is safe, feasible, well tolerated, and resulted in clinically meaningful improvements in multidimensional measures of cough, sputum production, breathlessness and quality of life https://bit.ly/30KBfPs